Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers, dialysis machines, hemodialysis machines, A.V. fistula needle sets, extracorporeal blood circuits, bloodlines, and plasma separators; peritoneal dialysis (PD) solutions; and PD consumables, such as bag free set, c… Read more
Shandong Weigao Blood (603014) - Total Assets
Latest total assets as of June 2025: CN¥8.12 Billion CNY
Based on the latest financial reports, Shandong Weigao Blood (603014) holds total assets worth CN¥8.12 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Weigao Blood - Total Assets Trend (2021–2024)
This chart illustrates how Shandong Weigao Blood’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Weigao Blood - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Weigao Blood's total assets of CN¥8.12 Billion consist of 42.6% current assets and 57.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.7% |
| Accounts Receivable | CN¥899.70 Million | 12.9% |
| Inventory | CN¥757.07 Million | 10.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥295.66 Million | 4.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Shandong Weigao Blood's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Weigao Blood's current assets represent 42.6% of total assets in 2024, an increase from 33.4% in 2021.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2024, up from 5.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 5.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 12.9% of total assets.
Shandong Weigao Blood Competitors by Total Assets
Key competitors of Shandong Weigao Blood based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Shandong Weigao Blood - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shandong Weigao Blood generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shandong Weigao Blood generates $6.43 in net profit.
Shandong Weigao Blood - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 2.12 | 2.12 |
| Quick Ratio | 2.72 | 1.47 | 1.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.89 Billion | CN¥ 1.35 Billion | CN¥ 1.35 Billion |
Shandong Weigao Blood - Advanced Valuation Insights
This section examines the relationship between Shandong Weigao Blood's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | CN¥6.99 Billion |
| Market Capitalization | $52.15K USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Weigao Blood's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Weigao Blood's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Weigao Blood (2021–2024)
The table below shows the annual total assets of Shandong Weigao Blood from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.99 Billion | +4.61% |
| 2023-12-31 | CN¥6.68 Billion | +4.24% |
| 2022-12-31 | CN¥6.41 Billion | +7.91% |
| 2021-12-31 | CN¥5.94 Billion | -- |